lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Foghorn Therapeutics, Inc.
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 9, 2026
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
March 11, 2026
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
February 24, 2026
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
February 23, 2026
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
February 3, 2026